AIM AIM ImmunoTech

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Live video webcast on Monday, June 17th at 1:00 PM ET

OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that of AIM will participate in the on Monday, June 17, 2024 at 1:00 PM ET.

As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.

A of the presentation will be available on the page of the Company’s website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit  and connect with the Company on , , and .



Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
EN
10/06/2024

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference Live video webcast on Monday, June 17th at 1:00 PM ET OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that of AIM will participate in the on Monday, June 17, 2024 at 1:00 PM ET. As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many que...

June 10, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Seri...

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that of AIM will participate in the on Wednesday, June 5, 2024 at 12:00 PM ET. As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the...

June 3, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Off...

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common stock and, unregiste...

May 31, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that will participate in two upcoming investor conferences. Details for the presentations are as follows: Event: Date and Time: Tuesday, May 21, 2024, at 3:20 PM ET Event: Date and Time: Wednesday, May 22, 2024, at 3:40 PM ET Live webcasts of the presentations will be accessible on the page of the section of the Company’s website, . About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is a...

May 20, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provid...

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (d...

May 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch